The combination of an inhaled corticosteroid ... Trelegy also has a COPD triple therapy competitor approved in Europe, where Chiesi was first to market earlier this year with Trimbow.

Trimbow (beclometasone+formoterol+glycopyrronium) combines an inhaled corticosteroid (ICS ... The drug is likely to be the first COPD triple therapy on the market, after Europe’s CHMP committee ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part ...

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

one author disclosed being an expert witness in litigation against inhaler manufacturers. More information: Avik Ray et al, Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

More research is needed to determine drivers of inhaler costs and patient knowledge on available financial assistance, ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Having stock inhalers available at schools prevents asthma-related emergency room visits, which can reduce healthcare costs and keep kids in classrooms, according to research presented here at the ...